Repurposing enzymes to degrade complex biofilms containing two bacteria and improve antibiotic activity
Assessing the effect of adding chelating agent (Tris-CaEDTA) to nebulised tobramycin for improving bacterial killing and lung function in cystic fibrosis patients with Pseudomonas aeruginosa lung infection.
Ototoxicity in Cystic Fibrosis Patients Receiving Intravenous Tobramycin for Acute Pulmonary Exacerbation
Prospective cohort study of ototoxicity in persons with cystic fibrosis following a single course of intravenous tobramycin
Impact of azithromycin on the clinical and antimicrobial effectiveness of tobramycin in the treatment of cystic fibrosis